[Anti-interferon antibody in chronic hepatitis C]

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic hepatitis C is a significant global health concern.
• Interferon (IFN) therapy has been used for hepatitis C treatment.
• The development of anti-IFN antibodies can impact treatment efficacy.

Purpose of the Study:

• To investigate the incidence of anti-interferon (IFN) antibodies in patients with chronic hepatitis C.
• To evaluate the clinical significance of anti-IFN antibodies, particularly regarding treatment resistance.
• To assess the utility of Western blotting for detecting anti-IFN antibodies.

Main Methods:

• Serial serum samples from 34 patients with chronic hepatitis C were analyzed.
• Patients were treated with various forms of IFN, including HLBI, recombinant IFN-alpha 2a, recombinant IFN-alpha 2b, and HuIFN-beta.
• Anti-IFN antibodies were detected using Western blotting.

Main Results:

• Anti-IFN antibodies were detected in 8.1% (9 out of 111) of the samples.
• Two patients treated with recombinant IFN-alpha 2a developed neutralizing anti-IFN antibodies and clinical resistance to IFN therapy.
• No anti-IFN antibodies were observed in patients treated with HLBI, recombinant IFN-alpha 2b, or HuIFN-beta.

Conclusions:

• The development of neutralizing anti-IFN antibodies, particularly with recombinant IFN-alpha 2a, is associated with treatment resistance in chronic hepatitis C.
• Western blotting is a valuable method for identifying anti-IFN antibodies and assessing their clinical relevance.
• Different types of IFN may have varying risks for inducing anti-IFN antibody formation.